Ghostboard pixel

πŸ“Š Health Data Analysis + Europe Health Tech 200

AI integration into healthcare management systems is expected to reduce administration workflows, freeing practitioner time to dedicated to patients.

Happy Monday πŸ‘‹

AI integration into healthcare management systems is expected to reduce administration workflows, freeing practitioners to devote more time to patients. In the Health Tech market, we revisit the 2023 Europe Health Tech 200, highlighting the region's most promising startups in the health technology sector.

This Week's Topics

πŸ“Š Health Data Analysis. AI drives innovation but is constrained by poor data quality
πŸ“ˆ Pharmaceutical Index. Pharmaceuticals up 7%
πŸ† Europe Health Tech 200. Europe's most promising startups working in digital health, biotech, drug discovery, and analytics
πŸ“– Annual Health Tech Outlook. 190+ pages of trends, insights, and data
πŸ’° Health Tech Deals of the Week. Funding and M&A

Don't forget to check out the 2024 Global Health Tech Outlook and sign up for our Daily Newsletters, Chart of the Day, and Impact Capital Markets. For unlimited access to over one million charts, request a demo.

πŸ“Š Health Data Analysis

AI is gradually transforming healthcare data analysis, promising to streamline workflows and free up clinician time for direct patient care. AI-powered systems analyze data from electronic health records and insurance claims, automating administrative tasks and generating deeper insights for providers. However, a critical challenge lies in data quality. The UK's National Institute for Health and Care Excellence (NICE) found that over half of treatment decisions rely on poor data. This highlights the risk that inaccurate data can hinder AI's ability to generate reliable insights. Therefore, improving data collection protocols and data quality is essential to fully unlock the potential of AI in healthcare analytics.

πŸ’Š Pharma Grows 7% YOY

HolonIQ’s Pharma Index has grown 7% over the past 12 months. After peaking in early 2021, Pharma stocks saw a significant decline until October 2023, a trend reflected in the index. The pandemic highlighted the need for new therapies and vaccines, spotlighting pharmaceutical companies. 

Eli Lilly ($840B MCap) and Novo Nordisk ($488B MCap) have driven growth with their GLP-1 drugs for obesity treatment, reflecting a 90% and 82% YOY stock price growth, respectively, highlighting their strong financial performance in the market. Their strategic initiatives, such as Eli Lilly's direct-to-consumer website and Novo Nordisk's partnerships, aim to expand market reach. Combined sales of their diabetes and obesity drugs are projected to reach approximately $36.9 billion by 2024, with expectations of nearly doubling by 2028.

Late 2023 witnessed heightened M&A activity, enabling companies to diversify pipelines and manage risks associated with patent expirations. Despite challenges such as high R&D investments and revenue pressures from declining COVID-19 treatment sales affecting major players like Pfizer, Moderna, and Merck, the outlook for biotech and pharma stocks in 2024 remains optimistic. Anticipated advancements in AI-driven technologies are poised to revolutionize biotech, enhancing drug development efficiencies and clinical study designs, further bolstering growth prospects for the sector.

πŸ† Europe Health Tech 200

The 2023 Europe Health Tech 200 is HolonIQ’s annual list of the region's most promising startups in digital health, biotech, drug discovery, and analytics.

Several cohort members entered into collaborations and acquisitions to offer more personalized services for patients. Samsung acquired the France-based ultrasound artificial intelligence firm Sonio SAS for $92.4 million. This acquisition will allow Samsung Medison’s ultrasound machines to integrate Sonio’s AI diagnostics capabilities. Deciphex partnered with the Swiss pharmaceutical giant Novartis to create AI drug discovery and development tools. Two of HolonIQ’s trends for health are AI-led drug discovery and AI-powered diagnostics, and it is apparent that these start-ups are gaining attention from major MedTech and Pharma companies to integrate these AI technologies into their operations.

πŸ“Š 2024 Global Health Tech Outlook

HolonIQ's annual analysis of the evolving Health Tech landscape offers over 190 pages of in-depth insights on market data, investments, strategic shifts, and trends in healthcare services, pharmaceuticals, biotechnology, and medical hardware. Download the extract or purchase the full report.

πŸ’° Health Tech Deals of the Week

HolonIQ actively monitors and tracks deals in the health industry across all regions of the world. Subscribe to our daily Impact Capital Markets newsletter to catch up on the top deals each day.


🧬 Marea Therapeutics, a US-based biotech firm using genetics for new cardiometabolic disease medications, raised $190M in Series B funding led by Sofinnova Investments to advance its MAR001 Phase II development plan.

🧠 Talkiatry, a US-based provider of mental health care services, raised $130M in a Series C funding led by undisclosed investors to help strengthen its value-based care approach for behavioral health and support its further development.

πŸ‘Ά Insightec, an Israel-based developer of MRI-guided focused ultrasound devices designed to provide non-invasive treatments, raised $150M in Equity Crowdfunding led by Fidelity Management & Research Company to expand operations and its development efforts.

πŸ”¬ Elion Therapeutics, a US-based biotechnology company that treats IFIs that pose a life-threatening risk, raised $81M in Series B funding to aid in developing SF001, a polyene antifungal with a low toxicity profile.

πŸŽ—οΈ InduPro, a US-based biopharma company manipulating protein pairings to create novel signaling pathways, raised $85M in Series A funding to support advancing the first cancer drug candidate targeting co-targeted pairs to IND filing in Q4 2025.


🧡 Boston Scientific, a US-based innovator of medical solutions that improve patients' health, acquired Silk Road Medical for $1.26B, a company specializing in TCAR procedures.

IPOs/Other Public Offerings

πŸ’Š Tempus, a US-based technology company advancing precision medicine, announced that it raised $410M in an IPO.

Thank you for reading. Have a great week ahead!
Have some feedback or want to sponsor this newsletter? Let us know at